Bought 200 lots today, at USD 75.6 a share. The reason is that this company is patent in investing in new companies, while it generates almost 3 billions of net cash each quarter.
The US stock markets are rising, even with interest rates are started to hike.
Gilead is at it multiple year low.
The assumption is that the shares will start to bottom out and move above the declining band line (around 76) in the coming days or 1-2 weeks.
Gilead has been growing extremely well in the past, but now it has overgrown itself. Its main products are to cure liver disease, but by doing so it has reduced the number of patients !
Its grown has stalled, but the share prices have dropped much more that the slowdown of growth.
It has so much cash and so many potential new drugs in the development.
P/E ratio is incredibly low at about 6.6 ! With so much cash in the bank ! (I even do not want to check out its financial details ! )
Gilead 2016Q4 and annual report on 2017.2.7
Not encouraging.
http://investors.gilead.com/External.File?t=2&item=g7rqBLVLuv81UAmrh20MpxkySR/Juf+xU+v7C8kt9FEaC2Kje2aJ+HX3UHZ7cym+8G7jfBqv2Fz/8p3yn7p4GA==&cb=636220992381618995
A length (comprehensive) study of Gilead by Seeking Alpha, read at
http://seekingalpha.com/article/4035271-gilead-sciences-top-biotech-pick-next-decade?page=1
how risky is agile ad ?
Read at http://www.nasdaq.com/article/how-risky-is-gilead-sciences-inc-cm722210
And Mark just won a USD 2.5 B patent claim against Gilead after the market close.
We must sell Gilead shares as our buying has not proven right.
Bought 200 lots today, at USD 75.6 a share. The reason is that this company is patent in investing in new companies, while it generates almost 3 billions of net cash each quarter.
The US stock markets are rising, even with interest rates are started to hike.
Gilead is at it multiple year low.
The assumption is that the shares will start to bottom out and move above the declining band line (around 76) in the coming days or 1-2 weeks.
Gilead 2016Q3 shows that non-H-C sales exceed H-C sales, at 3.5 and 3.3 B, respectively.
Read at
http://finance.yahoo.com/news/gilead-3rd-quarter-profit-falls-211350338.html
Consensus Earnings per share : 11.42 for 2016 and 11 for 2017,
There are not much downside risk.
Gilead has been growing extremely well in the past, but now it has overgrown itself. Its main products are to cure liver disease, but by doing so it has reduced the number of patients !
Its grown has stalled, but the share prices have dropped much more that the slowdown of growth.
It has so much cash and so many potential new drugs in the development.
P/E ratio is incredibly low at about 6.6 ! With so much cash in the bank ! (I even do not want to check out its financial details ! )
Buy the shares for long-term investment.